569 Multicenter Comparative Analysis of FRED-X, Pipeline Shield, and Surpass Evolve for the Treatment of Intracranial Aneurysms

View at publisher Summarise with VIRAT
Authors: Joanna Roy, Basel Musmar, Spyridon K. Karadimas, Sravanthi Koduri, Arbaz A. Momin, Alana McNulty, Allie Paul, Yi Zhang, Ajit S Puri, Jasmeet Singh, Anna Kuhn, Vinay Jaikumar
+6 more Jaims Lim, Elad I. Levy, M. Reid Gooch, Pascal Jabbour, Robert H. Rosenwasser, Stavropoula I. Tjoumakaris
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: In recent years, newer flow diverters have been developed with surface modification and varying wire densities. METHODS: This was a retrospective study of a prospectively maintained database from five participating institutions across the United States. Patients who underwent flow diversion of ruptured and unruptured intracranial aneurysms using the FRED-X, PED Shield or Surpass Evolve between February 2022 - September 2024 were included. Outcomes of interest were technical success, angiographic occlusion and in-stent stenosis (ISS) at 6- and 12- months. RESULTS: 447 patients with 452 aneurysms were included. Good wall apposition was achieved in 99.6% and 99.3% cases performed using PED Shield and FRED-X, compared to 81.3% of cases performed using Surpass Evolve (P < 0.001). 36.4% cases treated using Surpass Evolve required placement of adjunct devices, such as balloon angioplasty or stenting. At 6 months, complete angiographic occlusion was achieved in 69.3% of PED Shield patients, 63.6% of FRED-X patients, and 58% of Surpass Evolve patients (P = .254). ISS rates were comparable across cohorts (P = .826). At 12 months, complete occlusion was observed in 78.9% of PED Shield, 68.4% of FRED-X, and 64.5% of Surpass Evolve aneurysms. ISS cases at 12 months were mostly mild. Kaplan-Meier analysis showed no significant difference in occlusion rates among the three devices (P = .914). Rates of TIA, stroke, ICH and mortality were comparable across cohorts. CONCLUSIONS: Flow diversion using FRED-X, PED Shield and Surpass Evolve resulted in comparable rates of angiographic occlusion and ISS. However, adjunctive devices were more commonly needed with Surpass Evolve. Future studies through prospective registries are necessary to validate our findings.

Fields of Study & Subjects

Intracranial Aneurysms: Treatment and Complications Vascular Malformations Diagnosis and Treatment Aortic aneurysm repair treatments

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
171–172
Publication date
26 March 2026
Language
EN